INmune Bio (NASDAQ:INMB) Posts Earnings Results, Misses Estimates By $0.02 EPS

INmune Bio (NASDAQ:INMB) posted its quarterly earnings data on Thursday. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02), FiscalAI reports.

Here are the key takeaways from INmune Bio’s conference call:

• Positive sentiment: INmune Bio expects to submit its U.K. marketing authorization application for Ebstrocel in early February 2027, with potential approval around mid-2027. The company also targets a U.S. BLA submission in mid-2027, subject to FDA feedback.
• Positive sentiment: The MHRA has provided written alignment on planned clinical, non-clinical, and manufacturing elements, and the company says manufacturing and quality controls are being prepared for reliable supply. These steps support its application, but do not guarantee approval.
• Positive sentiment: A Uniphar agreement could enable named-patient access in eligible international markets before local approvals and create an earlier revenue opportunity. INmune cautioned that timing and scale depend on country-level arrangements, physician requests, and funding or reimbursement; no sales forecast was provided.
• Negative sentiment: INmune reported $16.3 million in cash at quarter-end and raised $4.5 million gross through an October stock-and-warrant offering, with cash expected to fund operations through Q3 2027. The company’s reduced quarterly loss and expenses were partly offset by the limited runway and potential share dilution.

INmune Bio Stock Down 11.7%

INmune Bio stock traded down $0.15 during mid-day trading on Thursday, reaching $1.18. The company had a trading volume of 469,848 shares, compared to its average volume of 265,973. INmune Bio has a 52 week low of $1.09 and a 52 week high of $2.60. The company has a 50 day moving average of $1.91 and a 200-day moving average of $1.63. The firm has a market cap of $32.85 million, a price-to-earnings ratio of -1.75 and a beta of 0.97.

Analyst Ratings Changes

Several brokerages recently weighed in on INMB. Weiss Ratings upgraded INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 19th. Wall Street Zen raised INmune Bio from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

About INmune Bio

INmune Bio, Inc is a clinical-stage biotechnology company focused on developing treatments that harness and modulate the innate immune system. The company’s research is aimed at addressing diseases in which chronic inflammation or impaired immune function plays a significant role, including cancer, neurodegenerative disorders and certain psychiatric conditions.

Its lead product candidate is XPro, a next-generation tumor necrosis factor inhibitor designed to selectively neutralize soluble TNF while preserving transmembrane TNF signaling.